LifeMD, Inc. Quarterly Report Released - Here’s What You Should Know

LifeMD, Inc. – Q2 2025 Investor Summary

Key Financial Metrics (Q2 2025 and YTD June 30, 2025):

• Revenues: Q2 2025 total revenues were $62.2 million (up from $50.7 million in Q2 2024). For the six months ended June 30, 2025, total revenues were $127.9 million, a 35% increase from $94.8 million in the comparable 2024 period.
  • Telehealth revenue (Q2): $48.6 million (78% of total)
  • WorkSimpli revenue (Q2): $13.7 million (22% of total)
• Gross Profit: Q2 2025 gross profit was $54.8 million (88.1% of sales), up from $45.6 million in Q2 2024 (90.1%). YTD gross profit: $111.8 million (87.4% of sales).
• Operating Loss: Q2 2025 operating loss was $(0.91) million (vs. $(6.3) million loss in Q2 2024). YTD operating income was $1.6 million (vs. $(12.5) million loss in 2024).
• Net Income (Loss): Q2 2025 net loss attributable to LifeMD, Inc. was $(2.07) million, compared to $(6.88) million one year earlier. YTD net loss attributable to LifeMD: $(690,070) vs. $(13.6) million in 2024.
• EPS: Basic and diluted loss per share attributable to common stockholders was $(0.06) in Q2 2025 and $(0.05) YTD, improved from $(0.19) and $(0.38), respectively, in the prior year.
• Cash: $36.2 million at June 30, 2025 (compared to $35.0 million at December 31, 2024).
• Working Capital: $(14.5) million at June 30, 2025 (down from $(11.5) million at year-end 2024).
• Current Ratio: Current assets $49.0 million, current liabilities $63.5 million.
• Outstanding Shares: 47,417,393 common shares as of August 4, 2025.

Balance Sheet and Cash Flow:

• Total Assets: $73.6 million ($62.8 million Telehealth, $10.8 million WorkSimpli)
• Total Liabilities: $73.2 million
• Stockholders’ Equity: $0.38 million (deficit narrowed from $(4.0) million at 2024 year-end)
• Net cash from operations: $11.7 million (vs. $9.7 million in 2024 YTD)
• Net cash used in investing: $(6.6) million
• Net cash used in financing: $(3.9) million

Business Highlights:

• Telehealth revenue growth of 48% year-over-year, driven by expanding subscription-based offerings and direct-to-patient platforms (LifeMD, Rex MD, ShapiroMD).
• GLP-1 Weight Management Program and LillyDirect partnership integration contributed to brand expansion and market reach.
• WorkSimpli subsidiary remained stable, increasing profitability (YTD segment operating income: $4.1 million vs $0.6 million in 2024).
• Over 80% of company revenue is on a subscription model, providing recurrent revenue streams.
• Significant investments in technology, CRM, and a new state-of-the-art pharmacy.

Risks:

• Material Weakness in Internal Controls: Management acknowledged previously identified material weaknesses in internal controls over financial reporting as of June 30, 2025. Management has been executing remediation measures including formalized policies/procedures and enhanced documentation; however, full remediation is ongoing. While no misstatements occurred, there is risk until fully remediated.
• Negative Working Capital: The company reported negative working capital of $(14.5) million, reflecting short-term obligations exceeding current assets, which may pressure liquidity if not offset by future cash generation.
• Dependence on Third Parties: Reliance on third-party manufacturers, pharmacies, and merchant processors introduces operational and supply chain risks, which are heightened by recent inventory and accounts receivable fluctuations.
• Legal and Regulatory Risk: Pending litigation (e.g., a putative class action from August 2023) and ongoing IRS dispute over a notice of deficiency.
• Debt Service: $15.9 million principal was outstanding as of June 30, 2025 on the Avenue Capital Credit Facility (since repaid in August 2025), incurring significant interest expense of $1.3 million YTD. Further capital needs could result in equity dilution or increased interest costs.
• Preferred Stock Dividends: $1.6 million in cumulative preferred dividends paid YTD, affecting common shareholder returns.
• Competition and Market Acceptance: Fast-evolving telehealth landscape, regulatory uncertainties, and changing consumer preferences could impact growth and profitability. Management specifically cites concerns about the acceptance of their offerings, pricing competition, and regulatory developments.

Management Discussion and Strategy:

• Revenue Growth Focus: Management attributed strong revenue growth to increased adoption of telehealth offerings and subscription-based models. Telehealth revenue represented 79% of total sales YTD.
• Expense Management: Operating expenses increased but as a percent of revenue declined (total expenses 86.2% of sales YTD vs 103.0% in prior year), reflecting operating leverage and efficiency initiatives. Notably, selling/marketing and development costs rose to support expansion, but general and administrative expenses decreased vs Q2 2024.
• Strategic Partnerships and Programs: Management highlighted integration with LillyDirect and growth of GLP-1 programs as key future drivers.
• Liquidity Actions: The company is actively managing liquidity through operations, ATM equity sales, and reduction of outstanding debt (notably, extinguished Avenue facility in August 2025).
• Continued Investment: Capital deployed into technology, automation, and pharmacy infrastructure; capex (including software) amounted to $5.6 million YTD.
• Improved Profitability: YTD operating income was positive for the first time despite continued preferred dividend obligations and interest costs.

Conclusion: LifeMD continues to show strong top-line growth in its core telehealth segment, improving profitability and cash generation, while managing costs and investing in future growth. Investors should note the ongoing internal control remediation, negative working capital position, and industry competitive/regulatory risks. The company's successful debt pay-down, high subscription revenue proportion, and continued product/technology expansion support its growth outlook, but liquidity and execution risks remain areas to monitor.

Visit Publicview AI to search and analyze millions of SEC filings using AI.